{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-086442","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.195123+00:00","generated_at":"2026-05-17T08:56:57.265446+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"TransCode shareholders elect directors and approve stock plan increase at 2025 annual meeting","bullets":["Elected directors Philippe Calais, Thomas Fitzgerald, Erik Manting, Magda Marquet; each received >84K votes for.","Approved amendment to 2021 stock plan increasing authorized shares by 166,724; 76,322 for, 18,310 against, 1,434 abstained.","Ratified WithumSmith+Brown as auditor for FY2025: 301,629 for, 7,844 against, 2,810 abstain; no broker non-votes.","Adjournment proposal passed but not needed because sufficient votes existed for the stock plan amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-086442","json":"https://secwatch.observer/filing/0001104659-25-086442.json","markdown":"https://secwatch.observer/filing/0001104659-25-086442.md","text":"https://secwatch.observer/filing/0001104659-25-086442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465925086442/0001104659-25-086442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465925086442/tm2524724d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:56:57.265446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}